Covaxin For children of 2 to 18 age group is pending for final approval by expert opinion and evaluation according to news agency ANI who quoted government sources. If Covaxin For children is approved it may bring a good news for all the parents who are worried about thier child’s health.
Earlier the Central Drugs Standard Control Organization (CDSCO) has recommended granting emergency use authorization (EUA) to Bharat Biotech’s Covaxin for vaccination of 2 to 18-year-olds against covid-19.
Bharat Biotech has already submitted data for clinical trials of the children between the 2-18 years age group for Covaxin to CDSCO. The Bharat Biotech said in the statement that the data has been thoroughly reviewed by the CDSCO and SEC and has provided their positive recommendations.
Another Hyderabad-based Biological E may also submit final data for its coronavirus vaccine Corbevax by November-end. The Phase 2/3 clinical trials of Corbevax, among adults 18 years to 80 years is also going on and the results are expected to be declared this month. Biological E has also sought permission from India’s drug regulator to conduct the phase-3 clinical trial for Corbevax as a single booster dose among those who have been fully vaccinated with Covishield or Covaxin.
Biological E has promised to supply 30 crore doses of Corbevax by December as per agreement with the Central government. The vaccine has been developed with support from the Department of Biotechnology and its PSU Biotechnology Industry Research Assistance Council (BIRAC) from the preclinical stage to phase-3 studies.
Other vaccines for children apart from Covaxin
Zydus Cadila’s ZvCoV-D
Zydus Cadila’s COVID-19 vaccine called ZvCoV-D has been approved for emergency use in age groups 12 and above in India.
Serum Institute of India’s (SII) Covovax
Serum Institute of India’s (SII) COVID-19 vaccine called Covovax has been cleared for trials in children aged 2-18. It is the Indian version of the Novovax vaccine which is developed in India by the Serum Institute for children.